Cosmetic and copper peptides compared

GHK-Cu vs AHK-Cu

Two copper tripeptide complexes, one found in human plasma and one with far fewer studies, with each figure tied to its own source.

A 2026 review describes GHK-Cu as the copper(II) complex of glycyl-L-histidyl-L-lysine, a small tripeptide that a 2018 review states occurs naturally in human plasma, and a 2007 study describes AHK-Cu as L-alanyl-L-histidyl-L-lysine-Cu2+.1,2,3 That 2026 review states that the clinical evidence for GHK-Cu remains sparse, and the AHK-Cu study found tested it on human hair follicles ex vivo and on cultured dermal papilla cells.1,3

The TGA names GHK-Cu among unapproved peptide products, and FDA names a risk of immunogenicity for injectable GHK-Cu.4,5 No label or regulator statement for AHK-Cu was found; the one registered human study found applies it in a mixed serum.6

FactGHK-CuAHK-Cu
What it isThe copper(II) complex of glycyl-L-histidyl-L-lysine, a small tripeptide naturally present in human plasma1,2L-alanyl-L-histidyl-L-lysine-Cu2+, a copper tripeptide complex3
How it comesNo label was found; widely used in skin and hair products, and as a 0.1% w/w topical gel in a registered trial2,8No label or product was found; a registered study lists it among small peptides in an aqueous topical serum6
Half-lifeNo human figure was found; a review expects free GHK to have a short systemic half-life, and in rat plasma GHK was rapidly degraded to HK1,9No figure was found; the only study found was ex vivo and in vitro, in human hair follicles and dermal papilla cells3
Studied doses
  • Registered wound trial: a thin film of 0.1% w/w gel, about 0.5 g, once daily for 14 days8
  • Split-face eyebrow study: a nominal 2% serum, in 18 healthy participants1
  • Hair follicles ex vivo: 10-12 to 10-9 M3
  • Registered study: a peptide serum including it, applied at approximately 1 to 3 mg/mL to defined skin sites6
StatusFDA: injectable GHK-Cu among substances nominated but withdrawn, with a risk of immunogenicity; other routes in category 1, under evaluation for compounding5,10. The TGA names it among unapproved peptide products4No label or regulator statement was found; the one registered study found is early phase 1, enrolling by invitation6

Get the app

Contents5
  1. 1How they differ
  2. 2Logged in Milligram
  3. 3What is not known
  4. 4References
  5. 5Related pages

Last reviewed . Sources are listed below.

How they differ

In vitro, 136.2 µg/cm² of copper from a 0.68% aqueous copper tripeptide permeated dermatomed human skin over 48 hours, and the 2026 review states that detecting total copper does not show that the intact complex crossed the barrier.7,1 A 2018 review states that GHK-Cu is very sensitive to breakdown by carboxypeptidase enzymes.2

The 2007 study proposed that AHK-Cu promotes the growth of human hair follicles, possibly by stimulating dermal papilla cell proliferation and precluding their apoptosis.3

Logged in Milligram

  • GHK-Cu: 15% of people who logged a dose in Milligram logged it in the 90 days to 15 November 2026.
  • AHK-Cu: Too few people logged it to show a share.

Shares of people who logged a dose in Milligram in the 90 days to 15 November 2026, shown only where at least 50 people logged three or more doses of the compound.

What is not known

The 2026 review states that formal absorption, distribution, metabolism and excretion studies of the intact GHK-Cu complex have not been reported, and FDA states that there are limited data in humans to inform safety for injectable GHK-Cu.1,5 One registered study applies both in a single peptide serum; no results are posted.6

References

  1. Mateescu DM, Gavrilescu DM, Mincioaga RI, et al. GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap. Systematic evidence-mapping review, 2026. PMC13610439
  2. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Review, 2018. PMC6073405
  3. Pyo HK, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Journal article (PubMed), 2007. PMID 17703734
  4. Therapeutic Goods Administration. Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. Regulator safety advisory, 2026. tga.gov.au
  5. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Regulator page, 2026. fda.gov
  6. Frontiers in Bioscience Research Institute and Aging. Systemic and Topical Geroprotective Rejuvenation Assessed by START/REST Aging Clocks. Registry entry (ClinicalTrials.gov), 2026. NCT07888595
  7. Hostynek JJ, Dreher F, Maibach HI. Human skin penetration of a copper tripeptide in vitro as a function of skin layer. In vitro study, 2011. PMC3016279
  8. Hudson Biotech. Topical GHK-Cu Gel for Acute Skin Wound Healing. Registry entry, 2026. NCT07437586
  9. Endo T, Miyagi M, Ujiie A. Simultaneous determination of glycyl-L-histidyl-L-lysine and its metabolite, L-histidyl-L-lysine, in rat plasma by high-performance liquid chromatography with post-column derivatization. Animal pharmacokinetic study, 1997. PMID 9187381
  10. US Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Regulator page, 2026. fda.gov